HomeHealthcare & Life SciencesPharmaceuticals Sarcoidosis Therapeutics Market

United States Sarcoidosis Therapeutics Market Size & Outlook, 2026-2034


United States Sarcoidosis Therapeutics Market Insights

  • Based on Reed Intelligence findings, the United States Sarcoidosis Therapeutics Market reached USD 436.45 Million in 2025 and is estimated to attain USD 936.44 Million by 2034.
  • From 2026 to 2034, the United States market is expected to grow at a steady CAGR of 8.73%.
  • Within the Drug Class category, Corticosteroids dominated in 2025 in terms of market size contribution.
  • Over the forecast period, Corticosteroids is forecasted to deliver the fastest growth, positioning it as the most lucrative Drug Class segment.

Other Key Findings


  • United States accounted for 30.74% of the global Sarcoidosis Therapeutics Market size in 2025.
  • By 2034, United States is expected to remain the top global market in terms of size.
  • Within North America, United States is forecasted to dominate the regional Sarcoidosis Therapeutics Market size by 2034.
  • Canada will be the fastest-growing market in North America, projected to achieve USD 275.89 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 436.45 Million
Market Size In 2034 USD 936.44 Million
Largest segment Corticosteroids
Units Revenue in USD Million
CAGR 8.73% (2026-2034)
Segmnetation Covered
Drug Class
  1. Corticosteroids
  2. Immunosuppressants
  3. Biologics
  4. Antimalarial Agents
Disease Type
  1. Pulmonary Sarcoidosis
  2. Cutaneous Sarcoidosis
  3. Cardiac Sarcoidosis
  4. Ocular Sarcoidosis
  5. Others
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports